Management of severe vulval lichen sclerosus with adalimumab

• DOI: 10.1111/ajd.13814
• Publication Date: 2022-03-09T12:06:30Z
• Authors: Nicholas Manuelpi...; Helen Saunders; Emma Veysey
• Keywords: 03 medical and health sciences; Lichen Sclerosus et Atrophicus; 0302 clinical medicine; Adalimumab; Quality of Life; Humans; Dermatitis; Female; Vulvar Lichen Sclerosus; 3. Good health

ABSTRACTVulval Lichen Sclerosus (VLS) is a chronic inflammatory dermatosis that significantly impacts the quality of life. We report 2 cases of severe treatment‐resistant VLS treated with subcutaneous adalimumab. One patient showed modest clinical improvement with no significant improvement in quality‐of‐life measures. The second patient showed a significant improvement in both clinical and quality‐of‐life measures. Both patients achieved optimal control with a maintenance dosing of 40 mg subcutaneously weekly. Adalimumab may be a treatment option for recalcitrant VLS; however, clinical trials are required to confirm efficacy for this indication.